Abstract
Prostate cancer and chronic prostatitis are prevalent disorders in men. The cause of prostate cancer and chronic prostatitis is multifocal and diverse. Both disorders exhibit characteristic elevation of serum prostate-specific antigen, currently the primary screening test for prostate cancer. Prostate inflammation, regardless of cause, is the histopathologic hallmark of chronic prostatitis. In general, inflammation is associated with multiple cancers, and prostate inflammation, in particular, is a suggested factor in the development and progression of prostate cancer. This review addresses the link between chronic prostatitis and prostate cancer, especially as it relates to clinical practice.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
American Cancer Society. Cancer facts and figures, 2006. Available at http://www.cancer.org/docroot/STT/stt_0_2006.asp?sitearea=STT&level=1. Accessed May 13, 2008.
Penson DF, Chan JM: Prostate Cancer. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. Washington, DC: US Government Printing Office, 2007. [NIH Publication No. 07-5512:71-122.]
DeMarzo AM, Platz EA, Sutcliffe S, et al.: Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7:256–269.
McNaughton-Collins M, Joyce GF, Wise M, Pontari MA: Prostatitis. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. Washington, DC: US Government Printing Office, 2007. [NIH Publication No. 07-5512:9–42.]
Roberts RO, Lieber MM, Bostwick DG, Jacobsen SJ: A review of clinical and pathological prostatitis syndromes. Urology 1997, 49:809–821.
Roberts RO, Lieber MM, Rhodes T, et al.: Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998, 51:578–584.
Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 2002, 60:78–83.
Sarma AV, McLaughlin JC, Wallner, et al.: Sexual behavior, sexually transmitted diseases, and prostatitis: the risk of prostate cancer in black men. J Urol 2006, 176:1108–1113.
Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860–867.
Basler JW, Piazza GA: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004, 171:S59–S63.
DeMarzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate. Implications for prostate carcinogenesis. Am J Pathol 1999, 155:1985–1992.
Shah R, Mucci NR, Amin A, et al.: Postatrophic hyperplasia of the prostate gland. Neoplastic precursor or innocent bystander? Am J Pathol 2001, 158:1767–1773.
Anton RC, Kattan MW, Chakraborty S, Wheeler TM: Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am J Surg Pathol 1999, 23:939–936.
Gerstenbluth RE, Seftel AD, MacLennan GT, et al.: Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002, 167:2267–2270.
Billis A, Magna LA: Inflammatory atrophy of the prostate. Arch Pathol Lab Med 2003, 127:840–844.
MacLennan GT, Eisenberg R, Fleshman RL, et al.: The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006, 176:1012–1016.
Konig JE, Senge T, Allhoff EP, Konig W: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004, 58:121–129.
Zheng SL, Liu W, Wiklund F, et al.: A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate 2006, 66:1556–1564.
Yoshimura R, Sano H, Masuda C, et al.: Expression of cox-2 in prostate carcinoma. Cancer 2000, 89:589–596.
National Institutes of Health Summary Statement. National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases workshop on chronic prostatitis. Bethesda, MD: December 1995.
Nickel JC, Nyberg LM, Hennenfent M: Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 1999, 54:229–233.
True LD, Berger RE, Rothman I, et al.: Prostate histopathology and chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol 1999, 162:2014–2018.
Carver BS, Bozeman CB, William BJ, Venable DD: The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol 2003, 169:589–591.
Okada K, Kojima M, Naya Y, et al.: Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000, 55:892–898.
Stancik I, Luftenegger W, Klimpfinger M, et al.: Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol 2004, 46:760–764.
Rowe WEJ, Laniado ME, Walker MM, Anup P: Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study. BJU Int 2006, 97:1039–1042.
Bozeman CB, Carver BS, Eastham JA, Venable DD: Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002, 167:1723–1726.
Nadler RB, Collins MM, Propert KJ, et al.: Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology 2006, 67:337–342.
Potts JM: Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol 2000, 164:1550–1553.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sandhu, J.S. Prostate cancer and chronic prostatitis. Curr Urol Rep 9, 328–332 (2008). https://doi.org/10.1007/s11934-008-0056-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11934-008-0056-6